Angioedema
2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 3 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Prothya BiosolutionsBelgium - Brussels
2 programs1
1
C1 inhibitor concentratePhase 31 trial
C1 inhibitor concentratePhase 2/31 trial
Active Trials
TakedaTOKYO, Japan
1 programLanadelumabPHASE_3Monoclonal Antibody5 trials
Active Trials
NCT04583007No Longer Available
+2 more trialsTrial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
TakedaLanadelumab
TakedaLanadelumab
Clinical Trials (2)
Total enrollment: 85 patients across 2 trials
Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema
Start: Feb 2021Est. completion: Jun 202212 patients
Phase 3Completed
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
Start: Feb 2021Est. completion: May 202373 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.